

## AMENDMENTS

***Please amend the Claims as follows:***

Claims 1-98. (Cancelled)

99. (New) An isolated *S. pneumoniae* consisting of amino acids 1-285 of SEQ ID NO: 243.

100. (New) A fusion protein comprising an isolated polypeptide according to claim 99 and a heterologous peptide consisting of 1 to 10 amino acids.

101. (New) The fusion protein of claim 100, wherein the peptide consists of 5 to 10 amino acids.

102. (New) The fusion protein of claim 100, wherein the peptide consists of 1 to 5 amino acids.

103. (New) The fusion protein of claim 100, wherein the peptide consists of 1 to 3 amino acids.

104. (New) The fusion protein of claim 100, wherein the peptide consists of 1 to 2 amino acids.

105. (New) A composition comprising:

a) an isolated *S. pneumoniae* polypeptide consisting of amino acids 1-285 of SEQ ID NO: 243; and

b) a pharmaceutically acceptable carrier or excipient.

106. (New) A composition comprising:

a) a fusion protein according to claims 100, 101, 102, 103, or 104 and

b) a pharmaceutically acceptable carrier or excipient.

107. (New) An isolated *S. pneumoniae* polypeptide consisting of amino acids 15-37, 32-57, 101-121, 115-135, 138-158, 152-172, 220-242 or 236-258 of SEQ ID NO: 243.

108. (New) A fusion protein comprising an isolated polypeptide according to claim 107 and a heterologous peptide consisting of 1 to 10 amino acids.

109. (New) The fusion protein of claim 108 wherein the peptide consists of 5 to 10 amino acids.

110. (New) The fusion protein of claim 108, wherein the peptide consists of 1 to 5 amino acids.

111. (New) The fusion protein of claim 108, wherein the peptide consists of 1 to 3 amino acids.

112. (New) The fusion protein of claim 108, wherein the peptide consists of 1 to 2 amino acids.

113. (New) An immunogenic composition comprising:

- a) an isolated *S. pneumoniae* polypeptide consisting of amino acids 15-37, 32-57, 101-121, 115-135, 138-158, 152-172, 220-242 or 236-258 of SEQ ID NO: 243e; and
- b) a pharmaceutically acceptable carrier or excipient.

114. (New) An immunogenic composition comprising:

- a) a fusion protein according to claims 108, 109, 110, 111, or 112; and
- b) a pharmaceutically acceptable carrier or excipient.